Trial · NCT06618521
Effect of Pilates Exercise Versus Circuit Exercise Training on Gestational Hypertension
NCT06618521, Not applicable, Completed, Cairo University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Pilates Exercise Versus Circuit Exercise Training on Gestational Hypertension. Trials, record NCT06618521. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06618521
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Pilates Exercise Versus Circuit Exercise Training on Gestational Hypertension
- NCT number
- NCT06618521
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 69 participants, actual
- Lead sponsor
- Cairo University
- Conditions
- Gestational Hypertension
- Interventions
- Anti-hypertensive drug (Methyldopa 250 mg), Pilates exercise, Circuit exercise training
- First posted
- 2024-10-01
- Last updated
- 2025-12-19
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Measurement of mean arterial blood pressure | 12 weeks | Pregnant women will be seated in a relaxed position with the arm supported on a table. A cuff will be secured around the bicep without excessive tightness. The cuff will be inflated while observing the aneroid monitor until the pressure reaches 20-30 mmHg above the usual blood pressure. A stethoscope will be placed below the cuff at the elbow crease, and the cuff will be gradually deflated. Systolic pressure will be recorded at the first Korotkoff sound, and diastolic pressure will be recorded when the sounds disappear. Mean arterial blood pressure will be measured for each pregnant woman in the three groups before and after the treatment procedures using the equation: MAP = 1/3 (SBP) + 2/3 (DBP). |
| Primary | Assessment of serum triglycerides level | 12 weeks | It will be assessed for each pregnant women in the three groups before and after the end of the treatment procedures.The blood samples will be collected after fasting for 9-12 hours. Participants will be asked to lie in half lying position with well supported back and arm, the antecubital area will be cleaned with alcohol. Blood sample of about 5cm will be drawn in the morning (at 8 clock) range between 7and 25 micrograms per deciliter (mcg-dl). Blood sample will be using disposable syringe and collected in sterilized tube. |
| Primary | Assessment of serum total cholesterol level | 12 weeks | It will be assessed for each pregnant women in the three groups before and after the end of the treatment procedures.The blood samples will be collected after fasting for 9-12 hours. Participants will be asked to lie in half lying position with well supported back and arm, the antecubital area will be cleaned with alcohol. Blood sample of about 5cm will be drawn in the morning (at 8 clock) range between 7and 25 micrograms per deciliter (mcg-dl). Blood sample will be using disposable syringe and collected in sterilized tube. |
| Primary | Assessment of serum low-density lipoprotein (LDL) level | 12 weeks | It will be assessed for each pregnant women in the three groups before and after the end of the treatment procedures.The blood samples will be collected after fasting for 9-12 hours. Participants will be asked to lie in half lying position with well supported back and arm, the antecubital area will be cleaned with alcohol. Blood sample of about 5cm will be drawn in the morning (at 8 clock) range between 7and 25 micrograms per deciliter (mcg-dl). Blood sample will be using disposable syringe and collected in sterilized tube. |
| Primary | Assessment of serum high-density lipoprotein (HDL) level | 12 weeks | It will be assessed for each pregnant women in the three groups before and after the end of the treatment procedures.The blood samples will be collected after fasting for 9-12 hours. Participants will be asked to lie in half lying position with well supported back and arm, the antecubital area will be cleaned with alcohol. Blood sample of about 5cm will be drawn in the morning (at 8 clock) range between 7and 25 micrograms per deciliter (mcg-dl). Blood sample will be using disposable syringe and collected in sterilized tube. |
| Secondary | Assessment of level of stress and anxiety | 12 weeks | Visual analogue scale (VAS) will be used to assess the level of stress and anxiety for each pregnant woman in the three groups. VAS is a straight line; its ends are defined as the extreme limits of stress, with 0 indicates no stress and anxiety, while 10 indicates maximum stress and anxiety. The pregnant woman will select and marks on the line the suitable description of her stress level before and after the end of the treatment course. |
| Secondary | Assessment of serum cortisol level | 12 weeks | It will be assessed for each pregnant women in the three groups before and after the end of the treatment procedures.The blood samples will be collected after fasting for 9-12 hours. Participants will be asked to lie in half lying position with well supported back and arm, the antecubital area will be cleaned with alcohol. Blood sample of about 5cm will be drawn in the morning (at 8 clock) range between 7and 25 micrograms per deciliter (mcg-dl). Blood sample will be using disposable syringe and collected in sterilized tube. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06618521
GET https://conductscience.org/api/trials/v1/NCT06618521/registered